Home » Topics » BioWorld Science

BioWorld Science
RSS

Genentech presents first phase I data for BITS-7201A

May 22, 2018

Immunomedics submits BLA for sacituzumab govitecan for metastatic TNBC

May 22, 2018

Merck & Co.'s rVSV-ZEBOV Ebola vaccine deployed in Democratic Republic of Congo

May 22, 2018

FDA accepts NDA for Rifamycin SV MMX

May 22, 2018

KRAS-G12C inhibitors reveal new approach to undruggable targets

May 22, 2018

FDA approves Lokelma for hyperkalemia

May 22, 2018

New anticancer adaptive cell therapy approach as cancer immunotherapeutic shows promise

May 22, 2018

Lundbeck begins clinical development with PDE1 inhibitor Lu-AF-76432

May 22, 2018

Prolia approved in U.S. for glucocorticoid-induced osteoporosis

May 22, 2018

FDA awards breakthrough therapy and fast track designations to Harmony's pitolisant

May 22, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....